Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Rising Care Costs Drive Cloud-Based MedTech Adoption

The cost of U.S. healthcare, which is expected to rise over the next three years according to research from Willis Towers Watson, is pushing care providers to look strategic solutions that make care more efficient without sacrificing patient care outcomes. Cloud-based medtech appears to be gaining steam to help meet patient demand and insulate against…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

The cost of U.S. healthcare, which is expected to rise over the next three years according to research from Willis Towers Watson, is pushing care providers to look strategic solutions that make care more efficient without sacrificing patient care outcomes. Cloud-based medtech appears to be gaining steam to help meet patient demand and insulate against future-facing risks.

According to a new report from Research and Markets, the U.S. healthcare facilities management market is estimated to experience significant growth due to an increasing prevalence of chronic conditions, rising healthcare expenditure and the demand for modern and technologically advanced solutions.

Because of this, and because of the cost (and disruption to care) of deploying hardware solutions across an entire hospital system, care facilities are turning to cloud-based medtech solutions, especially ones that improve facility oversight. With an eye for solutions that “improve collaboration among teams and subsidiaries working in various remote locations, lower organizations’ operational costs,” this cloud-based medtech investment trend is giving the larger healthcare facility management vertical a profitable estimation over the next five years.

On top of this, healthcare providers are citing already-existent technologies needing more interoperability to meet regulatory pressure, patient demand pressure, and the challenges that come from cloud technology that is unsupportive of data exchange. This is further motivating the desire for top-notch cloud-based medtech for healthcare facility management.

Kevin Stevenson, frequent contributor, healthcare administration expert and host of MarketScale’s “I Don’t Care” podcast, breaks down his thoughts on this trend toward cloud-based medtech, specifically equipment tracking solutions, in healthcare facility management spend, pulling from his hospital’s operational strategies and what the industry can learn from this trend in practice.

Kevin’s Thoughts

“Just wanna share a little bit of information on my thoughts regarding cloud-based facility management solutions. And this is in regards to devices that are capable of tracking medical equipment in real time.

And so I know for my facility, we are starting to use tags on a wide variety of equipment because, certainly in hospitals, equipment gets misplaced. It gets taken to other departments, it might be put in a closet by someone who doesn’t know where it’s actually is supposed to be stored. And so with these devices, being able to just take a look on a screen and find those in real time would be tremendously helpful for all of our staff members. It saved them a lot of time in trying to locate the equipment. Oftentimes, if somebody can’t find a piece of equipment they put in a requisition to purchase it, and so that’s also wasteful as well.

Another aspect of this that I’m particularly excited about is we’re going to be tagging all of our wheelchairs. Wheelchairs are the same thing. They float in and out of various departments in the hospital. And we also oftentimes find them outside of the hospital when they’re used by patient’s family members to take them to their cars or wherever upon discharge.

So I’m really excited about this new technology and I think whenever you’re considering that, you need to consider just the amount of equipment that you have, and particularly paying attention to those pieces of equipment that you’ve had a lot of leakage or just any kind of loss regarding that.”

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512